Table 3. Comparison of clinicopathological features between pseudo-fornix located MRGCs and non-pseudo-fornix located MRGCs of the non-ER group (n=12).
| Variables | Pseudo-fornix (n=6) | Non-pseudo fornix (n=6) | P-values | |
|---|---|---|---|---|
| Interval time (mo) | 60.0 (31–96) | 78.0 (24–111) | 1 | |
| Macroscopic type | 0.182 | |||
| Type 0-IIa/Type 0-IIc | 3 (50.0) | 6 (100.0) | ||
| Type 2/Type 3 | 3 (50.0) | 0 (0.0) | ||
| Tumor size (mm) | 36.0 (7–57) | 14.0 (9–24) | 0.060 | |
| Histological type | 0.060 | |||
| Differentiated type | 2 (33.3) | 6 (100.0) | ||
| Undifferentiated type | 4 (66.7) | 0 (0.0) | ||
| Tumor depth | 0.060 | |||
| ≤pT1b1(SM1) | 0 (0.0) | 4 (66.7) | ||
| ≥pT1b2(SM2) | 6 (100.0) | 2 (33.3) | ||
| Lymph node metastasis | 0.182 | |||
| Positive | 3 (50.0) | 0 (0.0) | ||
| Negative | 3 (50.0) | 6 (100.0) | ||
| Distal metastasis | 0.456 | |||
| Positive | 2 (33.3) | 0 (0.0) | ||
| Negative | 4 (66.7) | 6 (100.0) | ||
| Lymphovascular invasion | 0.567 | |||
| Positive | 2 (33.3) | 4 (66.7) | ||
| Negative or not evaluated | 4 (66.7) | 2 (33.3) | ||
| Treatment | 1 | |||
| Surgery | 4 (66.7) | 5 (83.3) | ||
| Chemotherapy or best supportive care | 2 (33.3) | 1 (16.7) | ||
Values are presented as number (%) or median (range).
MRGC = metachronous remnant gastric cancer; ER = endoscopic resection.